186643
Age and gender distribution of diabetes incidence in St Lucia
Stephen King, MD
,
Ministry of Health, Castries, St. Lucia
The Government of St Lucia performed a nation-wide screening program for diabetes and hypertension from May through December 2006. Nearly 31,000 St Lucians were screened by the program. After keypunch of the data sheets, analysis was performed using SAS. For participants that identified themselves as not having, or been diagnosed with, diabetes, incidence rates were developed adusting for age and gender. Rates were developed using 2005 estimates for population, the most recent currently available from the Government of St Lucia. The weighted annual incidence calculated from these data proved to be substantially higher than any published country-wide rates that could be found by the authors, world-wide. Several potential sources of bias in the calculated incidence rates were estimated. They failed to substantially diminish the observed incidence. Several sources of corroborative information (diabetes complication rates) were evaluated and found to be consistent with the estimated high incidence of diabetes in St Lucia. The authors discuss steps underway in St Lucia to more precisely document the diabetes incidence. The authors also discuss implications for a very high incidence of diabetes, as they might affect the community of nations in the Caribbean Basin.
Learning Objectives: 1.Discuss nation-wide diabetes screening in St Lucia
2.Identify patterns of incidence for Caribbean nation
3.Evaluate limitations in large scale screening programs for measuring annual diabetes incidence
Keywords: Diabetes, Developing Countries
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I performed the keypunch and analysis of all of the screening data from the 2006 St Lucia nation-wide diabetes and hypertension screening program.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|